Fulgent Genetics (FLGT) Operating Leases (2019 - 2026)

Fulgent Genetics has disclosed Operating Leases across 7 years of filings, most recently posting $6.0 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $6.0 million, up 54.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 million (up 54.33% YoY), and the FY2025 annual result was $3.8 million, down 8.23% from the prior year.
• Operating Leases came in at $6.0 million for Q1 2026 at Fulgent Genetics, up from $3.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $8.8 million in Q4 2022 to a low of $3.6 million in Q3 2025.
• The 5-year median for Operating Leases is $4.7 million (2024), against an average of $5.4 million.
• Across the five-year window, Operating Leases slumped 47.38% in 2025 and surged 54.33% in 2026, its largest moves.
• Fulgent Genetics' Operating Leases stood at $8.8 million in 2022, then retreated by 18.74% to $7.1 million in 2023, then slumped by 42.35% to $4.1 million in 2024, then declined by 8.23% to $3.8 million in 2025, then jumped by 58.9% to $6.0 million in 2026.
• The last three Operating Leases figures came in at $6.0 million (Q1 2026), $3.8 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.